Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743387 | 0.77 | — | — | |
| SCHEMBL1455874 | 0.76 | HRH1 (0.50) | NAAA | |
| SCHEMBL348396 | 0.70 | NAAA (0.38) | NAAA | |
| SCHEMBL7533053 | 0.70 | TSHR (0.37) | NAAA | |
| SCHEMBL4334481 | 0.70 | HRH1 (0.50) | NAAA | |
| SCHEMBL27348169 | 0.70 | NAAA (0.32) | NAAA | |
| SCHEMBL5536476 | 0.69 | HRH1 (0.53) | NAAA | |
| SCHEMBL5542816 | 0.68 | FDPS (0.39) | — | |
| SCHEMBL1455815 | 0.68 | LOXL2 (0.45) | NAAA | |
| SCHEMBL5544614 | 0.67 | HRH1 (0.56) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | VTVX HOLDINGS I LLC | 2010-12-30 | — | — | US | disclosed |
| EP-2019823-B1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
| EP-2019823-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2019824-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | NAAA 104/4885 |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, HK2 | NAAA 93/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | NAAA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.